US FDA Expedited Programs and Expanded Access

Ke Liu, MD, PhD
Chief, Oncology Branch
Division of Clinical Evaluation, Pharmacology and Toxicology
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research

Optimising the development of ATMPs to meet patient needs
London, United Kingdom
December 16, 2016
Disclosures

I have no financial relationships to disclose.

I will not discuss off-label use of products.
Outline

• US FDA Expedited Programs
  – Priority Review Designation: 1992
  – Accelerated Approval: 1992
  – Fast Track Designation (FTD): 1997
  – Breakthrough Therapy Designation (BTD): 2012

• US FDA Expanded Access
FDA Expedited Programs: Goals

- For drugs that address an unmet medical need in the treatment of a serious or life-threatening condition
- Intended to help ensure that drugs for these conditions are approved & available to patients as soon as it can be concluded that the therapies’ benefits justify their risks
- Allow for earlier attention to drugs that have promise in treating such conditions
  - Early consultation with FDA
FDA Expedited Programs Guidance

  - Single resource for information on FDA’s policies & procedures for four expedited programs
  - Describes threshold criteria applicable to concluding that a drug is a candidate for an expedited development and review program
FDA Expedited Programs

- Fast Track
- Breakthrough Therapy
- Priority Review
- Accelerated Approval

IND Submission

FDA Review
Breakthrough Therapy Designation (BTD)

- Qualifying criteria
- Features
- Breakthrough vs. Fast Track
BTD: Qualifying Criteria

A drug that

- Is intended to treat a serious condition AND
- Preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints
BTD: Qualifying Criteria

**Serious Condition**

- "condition": A disease or illness
- Including life-threatening conditions
- A clinical judgment, based on the condition’s impact on factors, such as:
  - Survival
  - Day-to-day function, **OR**
  - The likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one
BTD: Qualifying Criteria

- Intended to have an effect on a serious condition or a serious aspect of a condition
  - A direct effect on a serious manifestation or symptom of a condition
  - Other intended effects, such as
    - A product intended to improve or prevent a serious treatment-related side effect
    - A product intended to prevent a serious condition or reduce the likelihood that the condition will progress to a more serious condition or a more advanced stage of disease
BTD Qualifying Criteria

- Preliminary clinical evidence of substantial improvement over available therapy on one or more clinically significant endpoints
  - Is approved or licensed in the United States for the same indication, *AND*
  - Is relevant to current US standard of care (SOC) for the indication
BTD Qualifying Criteria

- Preliminary clinical evidence
  - Not sufficient (quality and/or quantity) to establish safety and effectiveness for purposes of approval
  - Generally derived from Phase 1 or 2 trials
  - Should involve a sufficient number of subjects to be considered credible
  - Ideally derived from a study comparing the drug to an available therapy (or placebo, if no available therapy), or from a study comparing the drug + SOC to the SOC alone
  - Single-arm studies comparing the study subjects’ clinical course with well-documented historical experience, if the magnitude of difference is large
BTD Qualifying Criteria

❖ Substantial improvement

- A matter of judgment
- Depends on:
  - The magnitude of the drug’s effect on a clinically significant endpoint (including duration of the effect) AND
  - The importance of the observed effect to the treatment of the serious condition or serious aspect of the condition
BTD Qualifying Criteria

- Approaches to demonstrate substantial improvement
  - Direct comparison of the drug to available therapy shows a much greater response
  - If there is no available therapy, the drug shows a clinically meaningful effect on an important outcome when compared to placebo
  - The drug plus available therapy result in a much greater response compared to available therapy alone
  - The drug reverses or inhibits disease progression, in contrast to available therapy that provides only symptomatic improvement
  - The drug has an important safety advantage compared with available therapy, and has similar efficacy
BTD Qualifying Criteria

- Clinically significant endpoint
  - An endpoint that measures an effect on irreversible morbidity or mortality (IMM) or on symptoms that represent serious consequences of the disease.
  - An endpoint that suggests an effect on IMM or serious symptoms, including:
    - An effect on an established surrogate endpoint that typically would be used to support traditional approval
    - An effect on a surrogate endpoint or intermediate clinical endpoint considered reasonably likely to predict a clinical benefit (i.e., the accelerated approval standard)
    - A significantly improved safety profile compared with available therapy (e.g., less dose-limiting toxicity for an oncology agent), with evidence of similar efficacy
Benefits / Features of Granted BTD

- All benefits of Fast Track designation
  - FDA takes actions to expedite development and review
  - Eligible for rolling review of NDA or BLA (submission and review of portions of an application before submission of the complete application)
- Intensive guidance on efficient drug development during IND, beginning as early as Phase 1
- Organizational commitment involving FDA senior managers
FTD vs BTD: Similarities

- Nature of programs: Designation
- Timeline for FDA response: Within 60 calendar days
- Intend to treat serious condition
- Benefits: FDA’s Actions to expedite development and review
  - Frequent interactions with the review team
  - May be eligible for priority review if supported by clinical data at the time of BLA / NDA submission
  - May qualify for rolling review
- Designation may be rescinded if no longer meeting the qualifying criteria
# FTD vs BTD: Differences

<table>
<thead>
<tr>
<th>Requirements for Designation</th>
<th>FTD</th>
<th>BTD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source of Data</strong></td>
<td>Non-clinical or clinical data</td>
<td>Preliminary clinical evidence</td>
</tr>
<tr>
<td><strong>Strength of Evidence</strong></td>
<td>The potential to address unmet medical need</td>
<td>Substantial improvement on a clinically significant endpoint(s) over available therapy</td>
</tr>
<tr>
<td><strong>Development Plan</strong></td>
<td>Specify how this potential will be evaluated in the drug development program (e.g., a description of the Phase 3 trials)</td>
<td>Not required</td>
</tr>
</tbody>
</table>

| Benefits | FDA takes actions to expedite development and review | All benefits of FTD  
- Intensive guidance on an efficient drug development program  
- Involvement of FDA senior managers |
Breakthrough Designation
Experience
in CBER OTAT
BT Requests in OCTGT (12/2012 – 06/2016)

- **Total Requests: 54**
  - 47 products
  - 7 Repeated requests

- **Requests Denied**: 2
- **Requests Granted**: 15
- **Requests withdrawn**: 37

![Pie chart showing the distribution of requests]

- Requests Denied
- Requests Granted
- Requests withdrawn
BTDs by Product Types

<table>
<thead>
<tr>
<th>Products</th>
<th>Requested BTDs</th>
<th>Granted BTDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene</td>
<td>26</td>
<td>12</td>
</tr>
<tr>
<td>Cellular</td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>Tumor Vaccine</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Oncolytic Virus</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>


**BTDs by Indications**

<table>
<thead>
<tr>
<th>Indications</th>
<th>Requests</th>
<th>Granted</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td>33</td>
<td>9</td>
</tr>
<tr>
<td><strong>Non-oncology</strong></td>
<td>21</td>
<td>6</td>
</tr>
<tr>
<td>Hematology</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Cardiology</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Neurology</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Transplantation</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Nephrology, Peripheral Vascular, Burn, Hepatology</td>
<td>1 in each specialty</td>
<td>0</td>
</tr>
</tbody>
</table>
Common Reasons for BTD Denial

- Evidence is too preliminary (quantity and/or quality) to be considered reliable
  - Small sample size
  - Lack of appropriate control
  - Post-hoc analyses of failed studies that identify a subset that may benefit
- Improvement over available therapy does not appear to be “substantial”
- Modification of product
What OTAT Has Learned

- BTD decisions are complex.
  - There is no one-size-fits-all characterization of a BT product.

- The reliability and persuasiveness of clinical evidence is critical to making the BTD decision.
  - There is not a definitive threshold for substantial improvement.
Expanded Access to Investigational Drugs
What is Expanded Access?

- Use of an investigational drug to treat a patient with a serious disease who has no other satisfactory options
- Intent is TREATMENT; also called “Compassionate Use”
- Contrast with using an investigational drug in a clinical trial, where the primary intent is RESEARCH
Types of Expanded Access Programs (EAPs)

There are three types of EAPs defined in the code of federal regulations:

- Individual
- Intermediate
- Treatment
Requirements for all EAPs
21 CFR 312.305

• Serious or immediately life-threatening illness or condition
• No comparable or satisfactory alternative therapy
• Potential benefit justifies the potential risks of the treatment (risks are not unreasonable in the context of the disease/condition being treated)
• Providing drug will not compromise product development
Drugs in EAPs are *investigational drugs*, and they are subject to the following requirements from 21 CFR:

- Part 50 - Protection of Human Subjects (informed consent)
- Part 56 - Institutional Review Board
- Part 312 - including Clinical Holds based on safety and reporting requirements (adverse event reports, annual reports)
Individual Patient EAPs
21 CFR 312.310

• Physician must determine probable risk from drug does not exceed that from disease
• FDA must determine that the patient cannot obtain access under another type of IND
• Procedures for emergency use (when there is not time to make a written IND submission)
  – FDA may authorize access without submission, with very quick turn-around (F/U written submission required within 15 working days of authorization)
Obtaining a Single Patient IND

1. **Physician and Patient / Family Discuss Risks & Benefits**
2. **Approval From IRB**
3. **Agreement From Drug Company**
4. **Submit Form 3926 to FDA, for approval**
5. **Treat Patient**

**To provide drug, and for FDA to reference commercial IND**

- **Form 3926 is 2 pages and includes:**
  - Brief medical history and rationale for trying drug
  - Proposed treatment plan with safety / efficacy monitoring

- **Also submit:**
  - Letter of authorization from sponsor
  - Investigator qualification statement / form 1571

**30-45 minutes!! Turn around time generally < 48h, 99.4% approval rate**
Intermediate Size Population

21 CFR 312.315

• Intended for situations where multiple patients with the same condition might benefit from a particular investigational product

• No set numerical parameters – meant to be practical
  – more than a few, and less than a lot
Treatment IND
21 CFR 321.320

- Drug is being investigated in clinical trial designed to support marketing, or trials are complete
- Company is actively pursuing approval
- Sufficient evidence of safety & effectiveness
Cautions for EAP Use

• Risk has not been established for investigational drug
  – Confidence in safety more important than consideration of efficacy
  – For a child with an immediate life-threatening condition, evidence burden is low

• Potential benefit is often overestimated
  – Drug given under EAP with intention to provide benefit
  – Anecdotal evidence of even overwhelming efficacy may hold up only in a very small subset of patients, but have toxicities that increase suffering and/or hasten death in everyone else

• Potential for negative impact on clinical development plan
Benefits and Barriers

**BENEFITS:**

- Provide access and hope to patients with no alternatives, willing to accept potentially greater risk
- May provide patients with a measure of autonomy over their own health care decisions
- Can be a foothold into marketplace for sponsors

**BARRIERS:**

- Paperwork/time (New! Form 3926)
- Manufacturing (drug availability)
- Fear that adverse events may disrupt clinical product development
CBER OTAT DCEPT

Oncology Branch Members

Peter Bross, MD (TL)
Ching-Hsien (Jessica) Lee, MD, PhD
Lydia Martynec, MD
Chaohong Fan, MD, PhD
Open Position (M.O.)

Adnan Jaigirdar MD
Sadhana Kaul, MD
Laronna Colbert, MD
Open Position (M.O.)
Open Position (TL)

Ke Liu, MD, PhD (BC)
OTAT Contact Information

Regulatory Questions:

• Contact the Regulatory Management Staff in OTAT: at CBEROCTGTRMS@fda.hhs.gov or Lori.Tull@fda.hhs.gov or by calling (301) 827-6536

• OCTGT Learn Webinar Series: http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/ucm232821.htm